Xiaoqing Yu Selected Research

Melanoma (Melanoma, Malignant)

1/2024	The functional role of L-fucose on dendritic cell function and polarization.
10/2023	Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
1/2022	Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis.
1/2021	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
1/2020	The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma.
1/2018	DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoqing Yu Research Topics

Disease

42	Neoplasms (Cancer) 05/2024 - 01/2005
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 05/2008
7	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2005
6	Lung Neoplasms (Lung Cancer) 04/2024 - 05/2008
6	Melanoma (Melanoma, Malignant) 01/2024 - 01/2018
5	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 08/2019
5	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2018
3	Carcinoma (Carcinomatosis) 11/2023 - 01/2021
3	Obesity 01/2023 - 01/2017
3	Esophageal Neoplasms (Esophageal Cancer) 11/2022 - 05/2008
3	Infections 12/2020 - 01/2017
2	Primary Myelofibrosis (Myelosclerosis) 05/2024 - 11/2018
2	Inflammation (Inflammations) 05/2024 - 09/2016
2	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 01/2020
2	Fatty Liver 01/2024 - 09/2018
2	Breast Neoplasms (Breast Cancer) 01/2024 - 05/2008
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2023 - 01/2023
2	Squamous Cell Carcinoma of Head and Neck 06/2023 - 07/2019
2	Mycosis Fungoides 01/2023 - 01/2021
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 12/2012
2	Pneumonia (Pneumonitis) 01/2022 - 05/2008
2	Prostatic Neoplasms (Prostate Cancer) 11/2021 - 01/2005
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2020 - 01/2018
2	Chronic Disease (Chronic Diseases) 10/2018 - 01/2018
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 01/2017
2	Patent Ductus Arteriosus 10/2016 - 01/2016
1	Penile Neoplasms (Penile Cancer) 05/2024
1	Glioblastoma (Glioblastoma Multiforme) 04/2024
1	Hyperthermia 03/2024
1	COVID-19 12/2023
1	Nasopharyngeal Carcinoma 06/2023
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2023
1	Crohn Disease (Crohn's Disease) 01/2023
1	Endometriosis 01/2023
1	Tertiary Lymphoid Structures 11/2022
1	Endometrial Neoplasms (Endometrial Cancer) 03/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2022

Drug/Important Bio-Agent (IBA)

11	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2017
9	Biomarkers (Surrogate Marker)IBA 05/2024 - 01/2018
9	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2018
8	ErbB Receptors (EGF Receptor)IBA 10/2023 - 04/2017
8	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2017
7	Immune Checkpoint InhibitorsIBA 01/2024 - 06/2017
4	Long Noncoding RNAIBA 03/2024 - 07/2019
4	Immunoglobulin A (IgA)IBA 11/2023 - 01/2021
3	Phosphotransferases (Kinase)IBA 05/2024 - 01/2018
3	Histones (Histone)IBA 04/2024 - 01/2016
3	LigandsIBA 04/2024 - 01/2005
3	VaccinesIBA 12/2023 - 01/2017
3	Immunoglobulin G (IgG)IBA 11/2023 - 03/2022
3	Carrier Proteins (Binding Protein)IBA 01/2023 - 09/2018
3	AntigensIBA 03/2022 - 01/2021
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2024 - 01/2023
2	CollagenIBA 03/2024 - 02/2016
2	ChemokinesIBA 01/2024 - 01/2021
2	Oncogene Proteins (Oncogene Protein)IBA 11/2023 - 01/2021
2	AntibodiesIBA 01/2023 - 01/2021
2	Anaplastic Lymphoma KinaseIBA 01/2023 - 04/2017
2	MicroRNAs (MicroRNA)IBA 01/2022 - 08/2019
2	CateninsIBA 01/2022 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 11/2021 - 01/2005
2	AndrogensIBA 11/2021 - 01/2005
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2012
2	Small Cytoplasmic RNAIBA 01/2021 - 07/2019
2	NucleotidesIBA 12/2020 - 10/2017
2	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 01/2017
1	AlarminsIBA 05/2024
1	Glucose (Dextrose)FDA LinkGeneric 04/2024
1	Notch ReceptorsIBA 04/2024
1	manganese ferriteIBA 03/2024
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2024
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2024
1	Butyric Acid (Butanoic Acid)IBA 01/2024
1	Histone Deacetylase InhibitorsIBA 01/2024
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2024
1	FucoseIBA 01/2024
1	Protein Isoforms (Isoforms)IBA 12/2023
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 12/2023
1	sintilimabIBA 10/2023
1	anlotinibIBA 10/2023
1	Cell-Free Nucleic AcidsIBA 06/2023
1	CD40 Ligand (CD40L)IBA 01/2023
1	SyndecansIBA 01/2023
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2023
1	InflammasomesIBA 01/2023
1	Neoplasm Antigens (Tumor Antigens)IBA 11/2022
1	Polymeric Immunoglobulin Receptors (Polymeric Immunoglobulin Receptor)IBA 03/2022
1	C-Reactive ProteinIBA 01/2022
1	Competitive Endogenous RNAIBA 01/2022
1	ProcalcitoninIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	hydrogen sulfite (bisulfite)IBA 01/2022
1	ChromatinIBA 01/2022
1	CholesterolIBA 11/2021

Therapy/Procedure

17	Immunotherapy 04/2024 - 03/2015
12	Therapeutics 03/2024 - 01/2005
3	Drug Therapy (Chemotherapy) 01/2021 - 01/2019
2	Chemoradiotherapy 11/2022 - 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2023
1	Oncolytic Virotherapy 01/2023